Development↦Statistic Methodology↦Statistics in the Protocol↦Study Termination Criteria
What is it? Why is it important?
Predefined rules regulate the premature discontinuation of a study. These rules are:
- Defined based on a risk-based approach (e.g. right and safety of study participants, data quality)
- Decumented in the study protocol and, if applicable, in the Statistical Analysis Plan (SAP)
- Assessed during planned interim analyses
Early termination criteria may include:
- Safety: unacceptable safety risks to participants (e.g. a higher number of adverse events in the intervention group compared to the control group, resulting in an unacceptable risk-benefit-ratio)
- Futility: an interim analysis indicates, with a high probability, that the intervention is ineffective or has only minimal benefit
- Efficacy: clear and statistically significant treatment benefit, making it unethical to continue the study with the inclusion of a control / placebo group
What do I need to do?
As a SP-INV, assess risks associated with your study, and if necessary define:
- Criteria warranting early study termination/discontinuation
- The need, timing, and frequency of interim analyses to assess study discontinuation criteria (i.e. when and how often to assess discontinuation criteria during study conduct)
- The requirement and composition of an Independent Data Monitoring Committee (IDMC) (i.e. also referred to as an independent Data Safety Monitoring Board (DSMB – with a focus on safety). An IDMC/DSMB evaluates the results of the interim analysis and makes impartial recommendations regarding the continuation/early termination of an ongoing study
Discuss potential termination criteria with a statistician and plan the:
- Required number and timing of interim analyses during study conduct
- Type of analysis performed during an interim analysis (e.g. analysis method)
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6 (R3) – see in particular
- 2.6 Investigator: Premature termination or suspension of a trial
- 3.10.1 Risk management
- 3.17.1 Reports: The premature termination or suspnesion of a trial
ICH Topic E9 – see in particular
- 4.1 Trial monitoring and interim analysis
- 4.5 Interim analysis and early stopping
- 7.2.1 Efficacy data
- 7.2.2 Safety data